Dr. Reddy's Laboratories Ltd (RDY): Price and Financial Metrics

Dr. Reddy's Laboratories Ltd (RDY): $67.37

0.50 (+0.75%)

POWR Rating

Component Grades














  • RDY scores best on the Stability dimension, with a Stability rank ahead of 97.19% of US stocks.
  • The strongest trend for RDY is in Quality, which has been heading down over the past 47 weeks.
  • RDY ranks lowest in Momentum; there it ranks in the 15th percentile.

RDY Stock Summary

  • With a price/earnings ratio of 3,518.37, Dr Reddys Laboratories Ltd P/E ratio is greater than that of about 99.96% of stocks in our set with positive earnings.
  • RDY's price/sales ratio is 320.1; that's higher than the P/S ratio of 98.45% of US stocks.
  • As for revenue growth, note that RDY's revenue has grown -98.4% over the past 12 months; that beats the revenue growth of merely 0.84% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Dr Reddys Laboratories Ltd, a group of peers worth examining would be GBX, SSTI, FMX, NUVA, and CPIX.
  • Visit RDY's SEC page to see the company's official filings. To visit the company's web site, go to www.drreddys.com.

RDY Stock Price Chart Interactive Chart >

Price chart for RDY

RDY Price/Volume Stats

Current price $67.37 52-week high $75.50
Prev. close $66.87 52-week low $57.54
Day low $67.00 Volume 114,400
Day high $67.76 Avg. volume 155,848
50-day MA $66.41 Dividend yield 0.42%
200-day MA $67.21 Market Cap 11.21B

Dr. Reddy's Laboratories Ltd (RDY) Company Bio

Dr. Reddy's Laboratories operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company was founded in 1984 and is based in Hyderabad, India.

RDY Latest News Stream

Event/Time News Detail
Loading, please wait...

RDY Latest Social Stream

Loading social stream, please wait...

View Full RDY Social Stream

Latest RDY News From Around the Web

Below are the latest news stories about Dr Reddys Laboratories Ltd that investors may wish to consider to help them evaluate RDY as an investment opportunity.

Beroni Group Received Approval for 43.5% R&D Rebate from Australian Government for the Novel, Potential Anti-Cancer Drug PENAO

NEW YORK and SYDNEY, Australia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based biopharmaceutical enterprise, today announced that PENAO Pty Ltd, its majority-owned, Sydney-based anti-cancer drug development company, has been approved by the Australian government for the annual 43.5% R&D rebate of eligible expenditure. The approval also includes R&D overseas activities so long as the total overseas expenditure claim over the life of the R&D

Yahoo | September 9, 2021

Citius Pharmaceuticals Acquires Dr. Reddy's Laboratories' License for Late-Phase 3 Oncology Immunotherapy (E7777) for the Treatment of Cutaneous T-Cell Lymphoma and other Cancer Indications

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR) today announced that it has entered into a definitive agreement with Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories, Ltd. (collectively, "Dr. Reddy's") (NYSE: RDY) to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. E7777, an engineered IL-2-diphtheria toxin fusion protein, is an improved fo

Yahoo | September 7, 2021

Dr Reddy''s inks pact worth USD150 million with Citius Pharma to sell all rights to anti-cancer agent E7777

Dr Reddy''s Laboratories on Saturday said it has inked a pact with US-based Citius Pharmaceuticals to sell its rights to an anti-cancer agent.

Zee Business | September 4, 2021

Dr. Reddy’s Laboratories enters into definitive agreement with Citius Pharmaceuticals, Inc. to sell its rights to anti-cancer agent E7777 (denileukin diftitox)

HYDERABAD, India & PRINCETON, N.J., September 04, 2021--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s"), announced that it has entered into a definitive agreement with Citius Pharmaceuticals, Inc. ("Citius") pursuant to which it sold all of its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets.

Yahoo | September 4, 2021

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian Market

HYDERABAD, India & MISSISSAUGA, Ontario, September 02, 2021--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced that Reddy-Lenalidomide, a generic equivalent to Revlimid® (lenalidomide) capsules, is approved by Health Canada and has been launched in the Canadian market. Reddy-Lenalidomide is one of the first generic medications of its kind to launch in Canada.

Yahoo | September 2, 2021

Read More 'RDY' Stories Here

RDY Price Returns

1-mo 7.45%
3-mo -4.99%
6-mo 15.11%
1-year 8.46%
3-year 92.59%
5-year 49.30%
YTD -4.72%
2020 76.61%
2019 8.38%
2018 1.18%
2017 -16.47%
2016 -1.67%

RDY Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full RDY Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.88 seconds.